retatrutide weight loss clinical data New Phase 3 from Eli Lilly is out this morning. Recall that retatrutide is a “triple agonist,” targeting GLP-1, GIP, and glucagon receptors simultaneously. Participants on the… Eli Lilly infiltrates anti-obesity market
Description
However, it has become well known for its ability to reduce feelings of hunger
Tesamorelin holds no UK marketing authorisation and would require importation as an unlicensed medicine on a named-patient basis, with full clinical and legal responsibility resting with the prescribing clinician
All of these factors contribute to significant weight loss
Fruhbeck G, Kiortsis DN, Catalan V
However, many of them have serious concerns about the long-term use of these drugs
Food thoughts may become less frequent
